The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
The conversation is about finding genuine sources to buy Pyrilutamide in India and possibly importing it as a group to reduce costs. The user seeks advice on shipping without prescription issues.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
Imidazole drugs like ketoconazole inhibit certain enzymes and prevent DHT from binding to SHBG, increasing free DHT in the bloodstream, which may contribute to balding. The discussion questions how these drugs help with hair loss despite this effect.
Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.
Purchasing Pyrilutamide for hair loss treatment in India, and exploring the possibility of utilizing Minoxidil, Finasteride, and RU58841 as alternatives.
The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.
PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.
The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.
Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
The user is considering starting pyrilutamide before a scheduled hair transplant, having previously used oral minoxidil and finasteride with worsening results. They also tried dutasteride, which worsened their hair and made their skin oily.
A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.
Microneedling combined with tretinoin is discussed for its effectiveness in treating hair loss. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments.
OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.
DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.
The conversation is about sourcing RU58841 for hair loss treatment in Australia and discusses the lack of effective alternatives. Alternatives mentioned include Kx826, fluridil, cb, alfatradiol, and topical spiro, but they are considered weak compared to RU58841.
How Pyrilutamide, a hair loss treatment, has improved texture and regrowth of hair without any side effects for users, who are encouraged to post progress photos.
The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.
The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
The user is seeking advice on which treatment to add to their current regimen for male pattern baldness. They have previously tried Dutasteride, Nizoral, and oral Minoxidil, but experienced continued hair loss. They are specifically asking for experiences with RU58841, Stemoxydine, or Alfatradiol.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.
Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
Redensyl, which is a topical alternative to Minoxidil for hair loss. It may have advantages such as not making the hair greasy and lasting longer after discontinuing use than minoxidil. There are some positive reports from users, but also some negative ones, so it's unclear how effective this treatment will be in comparison to Minoxidil and other treatments like Finasteride or RU58841.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.